Identification of common immunodominant antigens of *Eimeria tenella*, *Eimeria acervulina* and *Eimeria maxima* by immunoproteomic analysis

Lianrui Liu¹*, Xinmei Huang¹,²,*, Jianhua Liu¹, Wenyu Li¹, Yihong Ji¹, Di Tian¹, Lu Tian¹, Xinchao Yang¹, Lixin Xu¹, Ruofeng Yan¹, Xiangrui Li¹, Xiaokai Song¹

¹College of Veterinary Medicine, Nanjing Agricultural University, Nanjing 210095, China
²Institute of Veterinary Medicine, Jiangsu Academy of Agricultural Science, Nanjing 210014, China
*These authors have contributed equally to this work

Correspondence to: Xiaokai Song, email: songxiaokai@njau.edu.cn

Keywords: *Eimeria*, sporozoites, common immunodominant antigens, immunoproteomics

Received: January 25, 2017  Accepted: March 24, 2017  Published: April 04, 2017

Copyright: Liu et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC-BY), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

ABSTRACT

Clinical chicken coccidiosis is mostly caused by simultaneous infection of several *Eimeria* species, and host immunity against *Eimeria* is species-specific. It is urgent to identify common immunodominant antigen of *Eimeria* for developing multivalent anticoccidial vaccines. In this study, sporozoite proteins of *Eimeria tenella*, *Eimeria acervulina* and *Eimeria maxima* were analyzed by two-dimensional electrophoresis (2DE). Western blot analysis was performed on the yielded 2DE gel using antisera of *E. tenella*, *E. acervulina* and *E. maxima* respectively. Next, the detected immunodominant spots were identified by comparing the data from MALDI-TOF-MS/MS with available databases. Finally, *Eimeria* common antigens were identified by comparing amino acid sequence between the three *Eimeria* species. The results showed that analysis by 2DE of sporozoite proteins detected 629, 626 and 632 protein spots from *E. tenella*, *E. acervulina* and *E. maxima* respectively. Western blot analysis revealed 50 (*E. tenella*), 64 (*E. acervulina*) and 57 (*E. maxima*) immunodominant spots from the sporozoite 2DE gels of the three *Eimeria* species. The immunodominant spots were identified as 33, 27 and 25 immunodominant antigens of *E. tenella*, *E. acervulina* and *E. maxima* respectively. Fifty-four immunodominant proteins were identified as 18 ortholog proteins among the three *Eimeria* species. Finally, 5 of the 18 ortholog proteins were identified as common immunodominant antigens including elongation factor 2 (EF-2), 14-3-3 protein, ubiquitin-conjugating enzyme domain-containing protein (UCE) and glyceraldehyde-3-phosphate dehydrogenase (GAPDH). In conclusion, our results not only provide *Eimeria* sporozoite immunodominant antigen map and additional immunodominant antigens, but also common immunodominant antigens for developing multivalent anticoccidial vaccines.

INTRODUCTION

Avian coccidiosis, a major parasitic disease of chickens worldwide, was caused by intestinal infection of *Eimeria* spp. [1]. It causes reduction in weight gain and poor feed-conversion, and death of the chickens, leading to an estimated annual economic loss of more than US$3 billion to the global poultry [2, 3]. The species of *E. tenella*, *E. acervulina* and *E. maxima* are the most important in terms of global disease burden and economic impact [2, 4].

Present control strategy against this disease relies on anticoccidial drugs and live vaccines containing virulent or attenuated strains of *Eimeria* [5]. However, chemical residues, emergence of drug-resistant parasites and the high cost associated with the development of new drugs results in serious problems. Moreover, the live vaccines have inherent production limitations, risk of vaccinal pathogenicity as well as the potential reversion to a pathogenic form, and cost issues [2, 6, 7]. Thus, new vaccines containing either defined immunodominant antigens or based on recombinant DNA technology have
been or are being developed [2, 8, 9]. Clinical coccidiosis is mainly caused by co-infection with multiple species of *Eimeria* [10, 11], hence, a practical novel anticoccidial vaccine should contain the common antigens among *Eimeria* or antigens from multiple *Eimeria* species. Therefore, exploring immunodominant antigens, especially common antigens of *Eimeria*, is essential for developing novel vaccine against the simultaneous infection clinically.

Here, we described immunoproteomic analysis of *Eimeria tenella*, *Eimeria acervulina* and *Eimeria maxima*. A batch of immunodominant antigens was identified, with 33, 27 and 25 found in *E. tenella*, *E. acervulina* and *E. maxima*, respectively. Eighteen ortholog proteins and 5 common immunodominant antigens across the three *Eimeria* species were identified. Our results provide additional immunodominant antigens and common antigens for the development of multivalent vaccines against *Eimeria*.

## RESULTS

### Sporozoite 2DE gel profile of *E. tenella, E. acervulina* and *E. maxima*

The separation by 2-DE of 400 μg solubilized sporozoite proteins detected 629, 626 and 632 spots of *E. tenella, E. acervulina* and *E. maxima*, respectively. Most spots were located between 13 and 140 kDa (Figure 1). Analysis with ImageMaster 2D Platinum (Version 5.0, GE Amersham) revealed 22 spots shared among all these species.

### Detection of immunodominant spots by Western blot

Sporozoite 2DE gels of *E. tenella, E. acervulina* and *E. maxima* were analyzed by western blot using the corresponding antisera of these *Eimeria* species separately. Western blot profiles of the 2DE gel were shown in Figure 2. Immunodominant spots were observed on the western blot profiles of the three *Eimeria* species. Comparison with ImageMaster 2D Platinum revealed that 50 (*E. tenella*), 64 (*E. acervulina*) and 57 (*E. maxima*) immunodominant spots had high similarity between the 2DE gel profile and western blot profile. When the same western blot was probed with sera from negative control chickens, no proteins were detected (Figure 3).

### Immunodominant proteins analysis and identification using NCBI and Uniprot database

All the immunodominant spots (171) detected by western blot were analyzed by MALDI-TOF-MS/MS. The obtained peptide mass fingerprint dates were submitted to MASCOT Sequence Query server (http://www.matrixscience.com) for identification against nonredundant NCBI database (http://www.ncbi.nlm.nih.gov/BLAST) and the uniprot database (http://www.uniprot.org/). Identification required a MASCOT confidence interval of 95%. As shown in Table 1, 112 spots were identified in the databases as corresponding to 85 *Eimeria* proteins, including 33 of *E. tenella*, 27 of *E. acervulina* and 25 of *E. maxima*. Fifty-four out of the 85 immunodominant proteins were 18 kinds of ortholog proteins among the three *Eimeria* species. Table 2 showed amino acids similarity of the 18 ortholog proteins between the three *Eimeria* species. All the ortholog proteins shared sequence similarity of more than 63% between the three *Eimeria* species except peroxiredoxin. Five of the ortholog proteins even shared sequence similarity of more than 93% between the three *Eimeria* species, namely, elongation factor 2 (EF-2), 14-3-3 protein, ubiquitin-conjugating enzyme domain-containing protein (UCE), glyceraldehyde-3-phosphate dehydrogenase (GAPDH) and transhydrogenase. Therefore, the five proteins were identified as common immunodominant antigens among the three *Eimeria* species. Since there were no matched proteins in the database, 59 spots were not identified successfully.

## DISCUSSION

The immunity elicited by infections with *Eimeria* is species specific and an effective recombinant vaccine should include common protective antigens among several *Eimeria* species [12–14]. Some researchers have reported several *Eimeria* common antigens. Talebi reported a conserved immunodominant protein band (45 kDa) among sporulated oocysts of five *Eimeria* species (*E. acervulina, E. maxima, E. necatrix, E. praecox and E. tenella*) recognized by chicken anti-*E. maxima* serum. Sasai and colleagues reported a common antigen present on the apical complex of all chicken *Eimeria* sporozoites [15]. Constantinoiui and colleagues reported a highly conserved apical antigen among *Eimeria* species [16]. However, the reported common antigens are not specific. In the present study, we identified at least 5 specific *Eimeria* common immunodominant antigens by immunoproteomic analysis. Our research provided additional candidate common antigens for developing multivalent vaccines against simultaneous infection by several *Eimeria* species.

Since antibodies could confer protective immunity against *Eimeria* [17–20], in addition, the induced antibodies are relatively long lasting and easy for collection [13, 17, 21]. Therefore, in some previous reports, *Eimeria* antisera were used to identify immunodominant *Eimeria* antigens. For example, Réfega et al. obtained a total of 119 cDNA clones by immunoscreening *E. tenella* libraries using intestinal antibodies [22]. Laurent et al. screened a 19-kilodalton antigen present in several *Eimeria* species using sera raised to *E. acervulina* or *E. tenella* [23]. Some immunodominant antigens were screened from cDNA libraries by corresponding *Eimeria* antisera,
Figure 1: Sporozoite 2-DE gel profile of *E. tenella*, *E. acervulina* and *E. maxima*. (A) *E. tenella*, (B) *E. acervulina*, (C) *E. maxima*. Soluble proteins (400 μg) from sporozoite of the three species were resolved by IEF over a broad, non-linear pH 3-10 range followed by molecular mass on a 12.5% w/v acrylamide gel under denaturing conditions. Protein spots are visualized using silver stain.

Figure 2: Western blot analysis of the sporozoite 2DE gels of *E. tenella*, *E. acervulina* and *E. maxima* with anti-*E. tenella*, anti-*E. acervulina* and anti-*E. maxima* sera. (A) *E. tenella*, (B) *E. acervulina*, (C) *E. maxima*.

Figure 3: Western blot analysis of the sporozoite 2DE gels of *E. tenella*, *E. acervulina* and *E. maxima* with sera from negative control chickens. (A) *E. tenella*, (B) *E. acervulina*, (C) *E. maxima*. 
| Spot ID       | Identified protein                                                                 | Database ID               |
|--------------|-------------------------------------------------------------------------------------|---------------------------|
| A929         | 14 kDa phosphohistidine phosphatase, putative (E. acervulina)                       | CDI76382.1                |
| M1436        | 14 kDa phosphohistidine phosphatase, putative (E. maxima)                          | CDJ61236.1                |
| T1468, T1669 | 14 kDa phosphohistidine phosphatase, putative (E. tenella)                         | CDJ40270.1, U6KXP8|U6KXP8 |
| T1475        | 14-3-3 protein (E. tenella)                                                        | gi|21541950                |
| A1222, A1392, A1395 | 14-3-3 protein, putative (E. acervulina)                               | XP_013250285               |
| M567         | 14-3-3 protein, putative (E. maxima)                                               | XP_013335589               |
| M1056, M1064, M1414 | 56 kDa gametocyte antigen (E. maxima)                                           | gi|25989587                |
| T1064        | 56 kDa gametocyte antigen, related (E. tenella)                                    | CDJ41536.1                |
| A620         | 56 kDa gametocyte antigen, related OS= E. acervulina                                | CDI76967.1                |
| M1131        | 56 kDa gametocyte antigen OS= E. acervulina                                        | Q66LHTQ6LH7                |
| T1472        | Actin depolymerizing factor (E. tenella)                                           | ABM09551.1                |
| A1510        | Actin depolymerizing factor, putative (E. acervulina)                              | CDI83856.1                |
| M1647, M1343 | Actin depolymerizing factor, putative (E. maxima)                                  | CDI60866.1                |
| M469         | Actin, putative OS= E. maxima                                                      | U6M665U6M655_              |
| T941         | Alanine dehydrogenase, putative (E. tenella)                                       | CDI43978.1                |
| A604         | Alanine dehydrogenase, putative OS= E. acervulina                                  | U6GMM75U6GMM75             |
| A1448        | Aldo/keto reductase family oxidoreductase, putative (E. acervulina)                | CDI80286.1                |
| T1145        | Aldo/keto reductase family oxidoreductase, putative (E. tenella)                   | CDI45355.1                |
| M584         | Aldo/keto reductase family oxidoreductase, putative OS= E. maxima                   | CDI57423.1                |
| T393         | Aspartyl proteinase (Eimipsis) OS= E. tenella                                      | Q9QGN67Q9QGN67              |
| A1458        | Cytosol aminopeptidase, putative (E. acervulina)                                   | CDI77668.1                |
| T362         | Cytosol aminopeptidase, putative (E. maxima)                                       | U6KUYU6KUY7                |
| M1619, M1641 | Dihydrolipoyl dehydrogenase OS= E. maxima                                         | CDI55972.1                |
| A1368        | Dihydrolipoyl dehydrogenase, putative (E. acervulina)                              | CDI82910.1                |
| T1376        | Dihydrolipoyl dehydrogenase, putative (E. tenella)                                | CDJ38931.1                |
| T415         | Dynein heavy chain protein, related OS= E. tenella                                 | U6KWK6U6KWQ                |
| A1970        | Elongation factor 1-alpha OS= E. acervulina                                        | U6GWZ2U6GWZ                |
| M480, M470   | Elongation factor 1-alpha, putative (E. maxima)                                   | gi|557198794                |
| M478         | Elongation factor 2, putative (E. maxima)                                          | gi|557157086                |
| T811         | Elongation factor 2, putative (E. tenella)                                          | gi|557140471                |
| A939, A965   | Elongation factor 2, putative OS= E. acervulina                                    | U6GRG2U6GRG2               |
| T47          | Enolase 2, putative (E. tenella)                                                    | CDJ38513.1                |
| A1456        | Enolase 2, putative OS= E. acervulina                                               | CDI82390.1                |
| M1548        | Enolase 2, putative OS= E. maxima                                                  | CDJ56218.1                |
| A744, A742   | Fructose-bisphosphate aldolase OS= E. acervulina                                   | CDI80998.1                |
| T398         | Fructose-bisphosphate aldolase OS= E. tenella                                      | CDJ43237.1                |
| M1000        | Fructose-bisphosphate aldolase, related (E. maxima)                                | CDJ59017.1                |
| A751, A748   | Glyceraldehyde-3-phosphate dehydrogenase OS= E. acervulina                          | CDJ78463.1                |
| T403         | Glyceraldehyde-3-phosphate dehydrogenase OS= E. tenella                            | CDJ43289.1                |
| M1249        | Glyceraldehyde-3-phosphate dehydrogenase, putative (E. maxima)                     | CDJ57266.1                |
| A1581, A1348 | Halocid dehalogenase-like hydrolase domain-containing protein, putative (E. acervulina) | CDI76940.1                |
| T1287        | Halocid dehalogenase-like hydrolase domain-containing protein, putative (E. tenella) | CDJ37571.1                |
| M471         | Halocid dehalogenase-like hydrolase OS= E. maxima                                  | CDJ61159.1                |
| T1185        | Hypothetical protein (E. tenella)                                                  | gi|357017711               |
| T1316        | Hypothetical protein (E. tenella)                                                  | AET5O460.1                |
| T1447        | Hypothetical protein (E. tenella)                                                  | AET5O635.1                |
| T1208        | Hypothetical protein (E. tenella)                                                  | gi|357017711               |
such as TA4 [24], LPMC-61 [25], rhomboid proteins ETRH01 of *E. tenella* [26] and so on, and these identified immunodominant antigen were further demonstrated to be able to confer protection against *Eimeria* challenge [27, 28]. Therefore, we also used the *Eimeria* antisera to screen the immunodominant antigens of *Eimeria* species and obtained 85 immunodominant proteins. Part of the identified antigens were also identified as immunodominant antigens in previous studies, including MIC3, pyruvate kinase, enolase, actin, aspartyl proteinase, 14-3-3 protein, lactate dehydrogenase and so on [29–31]. Some of the identified antigens have been demonstrated to be able to confer protection against *Eimeria* challenge, such as lactate dehydrogenase [32], microneme 2 [33], microneme 7 [34] and so on. Therefore, the immunodominant antigens identified in this study have the potential for conferring protection against *Eimeria* challenge.

In this study, most of the identified immunodominant antigens shared orthologous relationships across the three *Eimeria* species. Nearly all the ortholog proteins shared amid acid sequence similarity of more than 63%,

| A841 | Hypothetical protein, conserved (*E. acervulina*) | CDI78255.1 |
| T1263 | Hypothetical protein, conserved (*E. tenella*) | CDJ37254.1 |
| M1375 | KH domain-containing protein, putative (*E. maxima*) | CDJ59518.1 |
| T776 | KH domain-containing protein, putative (*E. tenella*) | CDJ38027.1 |
| A895 | KH domain-containing protein, putative OS=*E. acervulina* | CDI84033.1 |
| A1618 | Lactate dehydrogenase (*E. acervulina*) | ACM77785.1 |
| M783, M762 | Lactate dehydrogenase OS=*E. maxima* GN=LDH | Q8RJU3|Q8RJU3_E |
| T718 | Lactate dehydrogenase OS=*E. tenella* | CDJ37067.1 |
| A1736 | Microneme 2 (*E. acervulina*) | KRI632K2.1 |
| M1002 | Microneme protein 7 OS=*E. maxima* GN=mic7 | G0LEU8|G0LEU8 |
| T1502 | Microneme protein MIC3, partial (*E. tenella*) | gi|40549149 |
| T1449 | Mitochondrial branched-chain alpha-keto acid dehydrogenase E1, putative (*E. tenella*) | CDJ43491.1 |
| A626 | Mitochondrial branched-chain alpha-keto acid dehydrogenase E1, putative, partial (*E. acervulina*) | CDI8447.1 |
| T962 | Nucleoside diphosphate kinase OS=*E. tenella* | U6KJW7|U6KJW7 |
| M373 | Nucleoside diphosphate kinase, putative (*E. maxima*) | CDJ59193.1 |
| A927 | Peroxiredoxin, putative (*E. acervulina*) | CDI84011.1 |
| M1109 | Peroxiredoxin, putative OS=*E. maxima* | CDJ59087.1 |
| T360 | Peroxional catalase, putative OS=*E. tenella* | CDJ43752.1 |
| A1233, A922 | Proteasome subunit alpha type 7, putative (*E. acervulina*) | CDI79975.1 |
| T893, T624 | Proteasome subunit alpha type 7, putative (*E. tenella*) | U6KJYA5|U6KJYA5 |
| M475, M476, M434, M875 | Purine nucleoside phosphorylase, putative (*E. maxima*) | CDJ57289.1 |
| T1083 | Purine nucleoside phosphorylase, putative (*E. tenella*) | CDJ44020.1 |
| A996 | Purine nucleoside phosphorylase, putative OS=*E. acervulina* | CDJ78710.1 |
| T533 | Putative uncharacterized protein OS=*E. tenella* | H9B9X1|H9B9X1 |
| A603, A614, A618 | Pyruvate kinase, putative (*E. acervulina*) | CDI78351.1 |
| A1326 | Sporozoite antigen, partial (*E. acervulina*) | CAA33905.1 |
| T623 | Transhydrogenase (Fragment) OS=*E. tenella* | Q24937|Q24937 |
| T714 | Transhydrogenase OS=*E. tenella* GN=7B2 PE=4 | Q07600|Q07600 |
| A1078, A1717 | Trisphosphate isomerase (*E. acervulina*) | CDJ66160.1 |
| M1718 | Trisphosphate isomerase, putative (*E. maxima*) | CDJ60494.1 |
| T1028, T665 | Trisphosphate isomerase (*E. tenella*) | CDJ37985.1, H9BA04|H9BA04 |
| A958, A1772 | Trisphosphate isomerase OS=*E. acervulina* | U6H9H0|U6H9H0, CDJ79666.1 |
| M1606, M1212 | Trisphosphate isomerase, putative (*E. maxima*) | CDI8447.1 |
| A1481, A1438, A1452 | Ubiquitin-conjugating enzyme domain-containing protein, putative (*E. acervulina*) | gl|557117367 |
| M699 | Ubiquitin-conjugating enzyme domain-containing protein, putative (*E. maxima*) | CDJ61561 |
| T1063 | Ubiquitin-conjugating enzyme domain-containing protein, putative (*E. tenella*) | XP_013236351 |
| M995, M909 | Uncharacterized protein OS=*E. maxima* | U6M744L|U6M744 |
| M858 | Uncharacterized protein OS=*E. maxima* | U9ALYQ2|U9ALYQ2 |

Note: 1. Number of the spot in the 2-DE gel and the western blot membrane; 2. A: *E. acervulina*, T: *E. tenella*, M: *E. maxima.*
furthermore, five proteins shared sequence similarity of more than 93% and were identified as common immunodominant proteins among the three *Eimeria* species. In addition, we compared the available amid acid sequence of the five identified common immunodominant proteins among 7 chicken *Eimeria* species, and found that nearly all the sequence similarity among the 7 *Eimeria* species were more than 90% except *E. mitis* UCE, indicating the 5 protein were highly conserved among 7 chicken *Eimeria*. Our further studies demonstrated the identified common antigen 14-3-3 protein and GAPDH could confer effective protection against challenge by several *Eimeria* species (unpublished data). Taken together, our data demonstrated that immunoproteomics screening could be an efficient approach for identifying common immunodominant proteins of *Eimeria* species.

Biological functions of the five common antigens have been generally described in some protozoa. Eukaryotic elongation factor 2 plays crucial role in the elongation stage of mRNA translation in eukaryotes, by mediating the translocation of the ribosome relative to the mRNA after addition of each amino acid to the nascent chain [35, 36]. The 14-3-3 proteins are a family of conserved regulatory molecules expressed in all eukaryotic cells. And play important roles in extensively regulatory processes, such as mitogenic signal transduction, apoptotic cell death, cell cycle control, and protein localization [37, 38]. *E. tenella* 14-3-3 protein could interact with the telomerase RNA-binding domain of telomerase reverse transcriptase [39]. UCE is a member of the family of ubiquitin-conjugating (E2) enzymes characterized by the presence of a highly conserved ubiquitin-conjugating (UBC) domain. E2 enzymes are well-conserved in eukaryotes and involved in Ub/UBL-modification pathways, and play central roles in processes like regulating protein degradation, function, and localization, thereby controlling the biology of the eukaryotic cell [40]. GAPDH is a key glycolytic enzyme in the process of metabolism of coccidian, as several pathogenic protozoa entirely depend on glycolysis as the source of ATP in the host [41, 42]. Transhydrogenase catalyses transhydrogenation between analogues of NAD(H) and NADP(H). A transhydrogenase was found to be located in the *Eimeria* refractile body and might function in relation with the ATP hydrolysis and respiration in the process of oocysts sporulation [43]. However, their specific biological functions in *Eimeria* need further studies.

In previous studies, the similarities of conserved or common antigens ranged from 70% to 99% [44–46].

### Table 2: Amino acid sequence similarity of the 18 immunodominant ortholog proteins among *E. tenella* *E. acervulina* and *E. acervulina* species

| Immunodominant ortholog proteins | *E. tenella* and *E. acervulina* | *E. acervulina* and *E. maxima* | *E. tenella* and *E. maxima* |
|----------------------------------|---------------------------------|---------------------------------|---------------------------------|
| Elongation factor 2, putative     | 99%                             | 99%                             | 99%                             |
| 14-3-3 protein                   | 97.5%                           | 99.6%                           | 97.1%                           |
| Ubiquitin-conjugating enzyme domain-containing protein, putative | 96.6% | 97.4% | 98.3% |
| Glyceraldehyde-3-phosphate dehydrogenase | 94.1% | 95.9% | 92.6% |
| Transhydrogenase                 | 93.4%                           | 94.5%                           | 92.9%                           |
| Actin depolymerizing factor      | 89.8%                           | 93.2%                           | 88.1%                           |
| Triosephosphate isomerase        | 82.1%                           | 92.0%                           | 78.9%                           |
| Fructose-bisphosphate aldolase   | 77.8%                           | 99.6%                           | 80.4%                           |
| Purine nucleoside phosphorylase, putative | 79.3% | 81.2% | 81.2% |
| Aldo/keto reductase family oxidoreductase, putative | 78.5% | 79.3% | 85.7% |
| Dihydrolipoyl dehydrogenase      | 75.7%                           | 81.0%                           | 84.1%                           |
| Enolase 2                        | 76.4%                           | 86.2%                           | 72.7%                           |
| Haloacid dehalogenase-like hydrolase domain-containing protein | 74.5% | 82.0% | 76.2% |
| KH domain-containing protein, putative | 71.5% | 77.9% | 69.3% |
| Lactate dehydrogenase            | 68.2%                           | 80.6%                           | 63.6%                           |
| 14 kDa phosphohistidine phosphatase, putative | 64.0% | 76.5% | 64.2% |
| 56 kDa gametocyte antigen        | 68.0%                           | 77.3%                           | 65.9%                           |
| Peroxiredoxin                    | 13.8%                           | 89.3%                           | 16.2%                           |
species is, the more conserved the protein is. Thus, we used a high threshold of 93% to define the common antigens. Certainly, we can use a lower threshold less than 93%. If so, more antigens would be identified as common antigens.

It has been reported that some of the five common immunodominant antigens were protective in protozoa and other parasites. *Toxoplasma gondii* 14-3-3 protein was proved to be a potential vaccine candidate against toxoplasmosis [47]. *Leishmania* elongation factor 2 was identified as T cell-stimulating antigen and might constitute potential vaccine candidates for leishmaniasis [48]. Elongation factor 1-Alpha was reported as protective antigen in *Toxoplasma gondii* and *Cryptosporidium parvum* [49, 50]. GAPDH was proved to confer protection against *Haemochus contortus* and *Schistosoma mansoni* [51, 52]. Protozoal GAPDHs were suggested as a potential antiparasitic targets in *Plasmodium falciparum* [41, 42], *Leishmania mexicana* [53], *Trypanosoma brucei* and *Trypanosoma cruzi* [54, 55]. Chen et al. [56] reported that immunization with recombinant UCE induced protection against *Taenia pisiformis*. Our subsequent studies demonstrated that 14-3-3 protein and GAPDH could confer protection against coinfection of *E. tenella*, *E. acervulina* and *E. maxima* (unpublished data). Taken together, the five common immunodominant antigens could be selected as vaccine candidates against *Eimeria*.

We provided reference maps of sporozoite immunodominant proteins for *E. tenella*, *E. acervulina* and *E. maxima*. In some previous studies, sporozoites protein 2DE profiles of *Eimeria* have been reported [29, 57–60]. However, sporozoites immunodominant protein 2DE profiles were seldom reported. de Venevelles et al. analyzed the sporozoite 2DE map of *Etenella* and detected approximately 50 immunodominant protein spots. However, they only identified a few of the immunodominant spots by mass spectrometry [29]. In this study, 50, 64 and 57 sporozoite immunodominant protein spots of *E. tenella*, *E. acervulina* and *E. maxima* were detected and identified as corresponding to 33 immunodominant antigens of *E. tenella*, 27 of *E. acervulina* and 25 of *E. maxima* respectively. Our results provided additional sporozoite immunodominant antigens and sporozoite immunodominant proteins reference maps for *E. tenella*, *E. acervulina* and *E. maxima*.

**MATERIALS AND METHODS**

**Ethics statement**

Animal experiments were conducted following the guidelines of the Animal Ethics Committee, Nanjing Agricultural University, China. All animal experiments were evaluated and approved by the Institutional Animal Care and Use Committee of Nanjing Agricultural University (approval number: 2012CB120750).

**Chickens and parasites**

New-hatched Hy-Line layer chickens (commercial breed W-36) were reared in sterilized wire cages under coccidian-free conditions and provided daily with coccidiostat-free feed and water until the end of experiment. Oocysts of *E. tenella*, *E. acervulina* and *E. maxima* were propagated, harvested and sporulated using a previously described protocol [61], and then stored in 2% (w/v) potassium dichromate solution at 4°C no longer than 2 weeks. Purity of the parasites was determined by PCR based on the internal transcribed spacer-1 (ITS-1) as previously described [62, 63]. Sporozoites of the parasites were harvested from sporulated oocysts by *in vitro* excystation and purified over nylon wool and DE-52 cellulose columns [61].

**Antiserum preparation**

Three antisera were prepared by inoculation of two-week-old chickens with pure coccidian. Chickens were orally inoculated 6 times at 3-day intervals with $1 \times 10^4$ sporulated oocysts of *E. tenella*, *E. acervulina* or *E. maxima* per chicken. Negative control birds were maintained under the same conditions and inoculated with distilled water. One week post the last inoculation, blood was collected from wing vein of the chickens. Subsequently, the sera were collected and determined by ELISA. A seventh even eighth dose would be given unless titers of the sera were beyond 1: 64. Sera were stored at −20°C for Western blot analysis. Meanwhile, serum was collected from uninfected chickens as negative control [21, 64].

**Two-dimensional electrophoresis (2DE)**

Purified sporozoites of the three species were smashed in lysis buffer (7 M urea, 2 M thiourea, 4% CHAPS, 40 mM dithiothreitol (DTT), 0.2% Bio-Lyte 3–10 ampholytes and 1 mM PMSF) by ultrasonic in ice bath (200 W, work time 5 s, intervaltime 10 s, 50 cycles). Soluble proteins were obtained after centrifugation for 1 min (15,000 rpm) at 4°C. Then the soluble proteins were treated with 2D clean up kit and quantified using PlusOne™ 2-D Quant Kit (Amersham Pharmacia) [65].

For 2DE, 400μg of sporozoite proteins were loaded onto analytical and preparative gels. The Ettan IPGphor Isoelectric Focusing System (GE Amersham) and pH 3–10 immobilized pH gradient (IPG) strips (13 cm, nonlinear; GE Healthcare) were used for isoelectric focusing (IEF). The IPG strips were rehydrated for 12 h in 250 μl of rehydration buffer containing the protein samples. IEF was performed in four steps: 30V for 12 h, 500 V for 1 h, 1000 V for 1 h, and 8000 V for 8 h. The gel strips were equilibrated for 15 min in equilibration buffer (50 mM Tris-HCl (pH 8.8), 6 M urea, 2% SDS, 30% glycerol, and 1% DTT). This step was repeated using the same buffer with 4% iodoacetamide in place of...
1% DTT. The strips were then subjected to the second-dimensional electrophoresis after transfer onto 12.5% SDS-polyacrylamide gels. Electrophoresis was performed using the Hoefer SE 600 system (GE Amersham). The 2DE was performed twice for each sample simultaneously, and one of obtained gels was used for immunoblot analysis, while the other one prepared for silver staining.

**Western blot and image analysis**

Proteins in the 2DE gel were transferred electrophoretically onto a 0.45 μm pore size polyvinylidene fluoride (PVDF) membrane (GE Healthcare, USA) for 2 h at 100V using a TE62 Tank Transfer Unit system (GE Healthcare, USA). Membranes were then blocked in 5% skim milk in PBS containing 0.05% Tween 20 (PBST) for 1 h at room temperature with gently swinging. And then was incubated with anti-\(E.\) *tenella*, anti-\(E.\) *acervulina* and anti-\(E.\) *maxima* sera (1:100) for 2 h at 37°C. The uninfected chicken serum was used to test another membrane as a negative control. After frequent washing with PBST, the membrane were incubated with secondary antibody of Goat anti-chicken IgG (1:2000, PTG Inc., USA) for 2 h at 37°C. Finally, 3, 3′-diaminobenzidine (DAB, Sigma) was added to visualize the immunodominant protein spots, according to the manufacturer’s instructions.

Blots were scanned using TyphoonTMFLA 9500 (GE Amersham, USA). Through ImageMaster 2D Platinum (Version 5.0, GE Amersham, USA), the spots on the membranes were matched to their orthologs in 2DE gels stained using a modified silver staining methods compatible with subsequent mass spectrometric analysis [66].

**Two-dimensional gel excision, Tryptic Digestion, and Desalting**

All the the immunodominant spots on the PVDF membranes were excised from 2D gels from the preparative gels. Subsequently, the protein spots were destained for 20 min in 30 mM potassium ferricyanide/100 mM sodium thiosulfate (1:1 v/v) and washed with Milli-Q waters. The spots were incubated in 0.2 M \(\text{NH}_4\text{HCO}_3\) for 20 min and then lyophilized. Each spot was digested overnight in 12.5 ng/μl trypsin in 25 mM \(\text{NH}_4\text{HCO}_3\). The peptides were extracted three times with 60% acetonitrile (ACN)/0.1% trifluoroacetic acid (TFA). The extracts were pooled and dried completely by a vacuum centrifuge.

**MS analysis of protein spot and database searches**

MS analysis of protein spot was performed by APT (Applied ProteinTechnology co. Ltd, Shanghai, China). MS and MS/MS data for protein identification were obtained by using a MALDI-TOF-TOF instrument (5800 proteomics analyzer; Applied Biosystems). Instrument parameters were set using the 4000 Series Explorer software (Applied Biosystems). The MS spectra were recorded in reflector mode in a mass range from 800 to 4000 with a focus mass of 2000. MS was used a CalMix5 standard to calibrate the instrument (ABI 4700 Calibration Mixture). For one main MS spectrum 25 subspectra with 125 shots per subspectrum were accumulated using a random search pattern. For MS calibration, autolysis peaks of trypsin (\([\text{M}+\text{H}] + 842.5100\) and 2,211.1046) were used as internal calibrates, and up to 10 of the most intense ion signals were selected as precursors for MS/MS acquisition, excluding the trypsin autolysis peaks and the matrix ion signals. In MS/MS positive ion mode, for one main MS spectrum 50 subspectra with 50 shots per subspectrum were accumulated using a random search pattern. Collision energy was 2 kV, collision gas was air, and default calibration was set by using the Glu1-Fibrino-peptide B (\([\text{M}+\text{H}] + 1,570.6696\) spotted onto Cal 7 positions of the MALDI target. Combined peptide mass fingerprinting PMF and MS/MS queries were performed by using the MASCOT search engine 2.2 (Matrix Science, Ltd.) embedded into GPS-Explorer Software 3.6 (Applied Biosystems) on the database of uniprot \(Eimeria\) or NCBI with the following parameter settings: 100 ppm mass accuracy, trypsin cleavage one missed cleavage allowed, carbamidomethylation set as fixed modification, oxidation of methionine was allowed as variable modification, MS/MS fragment tolerance was set to 0.4 Da. a GPS Explorer protein confidence index ≥ 95% were used for further manual validation.

**Abbreviations**

\(E.\) *tenella*: \(Eimeria\) *tenella*; \(E.\) *acervulina*: \(Eimeria\) *acervulina*; \(E.\) *maxima*: \(Eimeria\) *maxima*; \(E.\) *mitis*: \(Eimeria\) *mitis*; 2DE: two-dimensional electrophoresis; MALDI-TOF-MS/MS: Matrix-Assisted Laser Desorption/ Ionization Time of Flight Mass Spectrometry/ Mass Spectrometry; NCBI: The National Center for Biotechnology Information; spp.: species; EF2: Elongation factor 2; UCE: Ubiquitin-conjugating enzyme domain-containing protein; GAPDH: Glyceraldehyde-3-phosphate dehydrogenase; PBS: phosphate buffer saline; ITS-1: internal transcribed spacer-1.

**Authors’ contributions**

SXK designed the study and critically revised the manuscript. LXR, YRF and XLX helped in the study design and analyzed the data. LLR performed the laboratory tests. HXM contributed to the preparation and purity identification of \(Eimeria\) species and wrote the draft. LJH, LWY and JYH contributed to the separation of the \(Eimeria\) sporozoites antigen. TD, TL and YXC contributed to the preparation of the antisera and western
blot analysis. All authors read and approved the final version of the manuscript.

ACKNOWLEDGMENTS

We gratefully thank Menghui Li, ZhenChao Zhang and JingWei Huang for sample collection and valuable suggestions. We gratefully thank Ehsan for his careful polish with the manuscript.

CONFLICTS OF INTEREST

The authors declare that they have no competing interests.

FUNDING

This work was supported by the National Natural Science Foundation of China (Grant No. 31672545; 31372428; 31661143017), the Natural Science Foundation of Jiangsu Province of China (Grant No. BK20161442), the Fundamental Research Funds for the Central Universities (Grant No. KYZZ1631) and the Priority Academic Program Development of Jiangsu Higher Education Institutions (PAPD).

REFERENCES

1. Dalloul RA, Lillehoj HS. Poultry coccidiosis: recent advancements in control measures and vaccine development. Expert Rev. Vaccines. 2006; 5:143–163.
2. Blake DP, Tomley FM. Securing poultry production from the ever-present Eimeria challenge. Trends Parasitol. 2014; 30:12–19.
3. Witcombe DM, Smith NC. Strategies for anti-coccidial prophylaxis. Parasitology. 2014; 141:1379–1389.
4. Reid AJ, Blake DP, Ansari HR, Billington K, Browne HP, Bryant J, Dunn M, Hung SS, Kawahara F, Miranda-Saavedra D, Malas TB, Mourier T, Naghra H, et al. Genomic analysis of the causative agents of coccidiosis in domestic chickens. Genome Res. 2014; 24:1676–1685.
5. Clark EL, Tomley FM, Blake DP. Are Eimeria Genetically Diverse, and Does It Matter? Trends Parasitol. Trends Parasitol. 2017; 33:231–241.
6. Clarke L, Fodey TL, Crooks SR, Moloney M, O’Mahony J, Delahaut P, O’Kennedy R, Danaher M. A review of coccidiostats and the analysis of their residues in meat and other food. Meat Sci. 2014; 97:358–374.
7. Ahmad TA, El-Sayed BA, El-Sayed LH. Development of immunization trials against Eimeria spp. Trials Vaccinol. 2016; 5:38–47.
8. Vermeulen AN. Progress in recombinant vaccine development against coccidiosis. A review and prospects into the next millennium. Int J Parasitol. 1998; 28:1121–1130.
9. Meunier M, Chemaly M, Dory D. DNA vaccination of poultry: the current status in 2015. Vaccine. 2016; 34:202–211.
10. Carvalho FS, Wenceslau AA, Teixeira M, Matos Carneiro JA, Melo AD, Albuquerque GR. Diagnosis of Eimeria species using traditional and molecular methods in field studies. Vet Parasitol. 2011; 176:95–100.
11. Ogedengbe JD, Hunter DB, Barta JR. Molecular identification of Eimeria species infecting market-age meat chickens in commercial flocks in Ontario. Vet Parasitol. 2011; 178:350–354.
12. del Cacho E, Gallego M, Lee SH, Lillehoj HS, Quílez J, Lillehoj EP, Sánchez-Acedo C. Induction of protective immunity against Eimeria tenella, Eimeria maxima, and Eimeria acervulina infections using dendritic cell-derived exosomes. Infect Immun. 2012; 80:1909–1916.
13. Constantinoiu CC, Lillehoj HS, Matsubayashi M, Hosoda Y, Tani H, Matsuda H, Sasai K, Baba E. Analysis of cross-reactivity of five new chicken monoclonal antibodies which recognize the apical complex of Eimeria using confocal laser immunofluorescence assay. Vet Parasitol. 2003; 118:29–35.
14. Chapman HD. Milestones in avian coccidiosis research: a review. Poult Sci. 2014; 93:501–511.
15. Talebi A. Protein profiles of five avian Eimeria species. Avian Pathol. 1995; 24:731–735.
16. Sasai K, Lillehoj HS, Matsuda H, Wergin WP. Characterization of a chicken monoclonal antibody that recognizes the apical complex of Eimeria acervulina sporozoites and partially inhibits sporozoite invasion of CD8+ T lymphocytes in vitro. J. Parasitol. 1996; 82:82–87.
17. Guzman VB, Silva DA, Kawazoe U, Mineo JR. A comparison between IgG antibodies against Eimeria acervulina, E. maxima, and E. tenella and oocyst shedding in broiler-breeders vaccinated with live anticoccidial vaccines. Vaccine. 2003; 21:4225–4233.
18. Wallach M, Pillemer G, Yarus S, Halabi A, Pugatsch T, Mencher D. Passive immunization of chickens against Eimeria maxima infection with a monoclonal antibody developed against a gametocyte antigen. Infect Immun. 1990; 58:557–562.
19. Crane MS, Murray PK, Gnozzio MJ, MacDonald TT. Passive protection of chickens against Eimeria tenella infection by monoclonal antibody. Infect Immun. 1988; 56:972–976.
20. Smith NC, Wallach M, Miller CM, Braun R, Eckert J. Maternal transmission of immunity to Eimeria maxima: Western blot analysis of protective antibodies induced by infection. Infect Immun. 1994; 62:4811–4817.
21. Constantinoiu CC, Molloy JB, Jorgensen WK, Coleman GT. Development and validation of an ELISA for detecting antibodies to Eimeria tenella in chickens. Vet Parasitol. 2007; 150:306–313.
22. Réfega S, Giraud-Misguich F, Bourdieu C, Péry P, Labbé M. Gene discovery in Eimeria tenella by immunoscreening
cDNA expression libraries of sporozoites and schizonts with chicken intestinal antibodies. Vet Parasitol. 2003; 113:19–33.

23. Laurent F, Bourdieu C, Kazanji M, Yvoré P, Péry P. The immunodominant Eimeria acervulina sporozoite antigen previously described as p160/p240 is a 19-kilodalton antigen present in several Eimeria species. Mol Biochem Parasitol. 1994; 63:79–86.

24. Brothers VM, Kuhn I, Paul LS, Gabe JD, Andrews WH, Sias SR, McCaman MT, Dragon EA, Files JG. Characterization of a surface antigen of Eimeria tenella sporozoites and synthesis from a cloned cDNA in Escherichia coli. Mol Biochem Parasitol. 1988; 28:235–247.

25. Ko C, Smith CK 2nd, McDonell M. Identification and characterization of a target antigen of a monoclonal antibody directed against Eimeria tenella merozoites. Mol Biochem Parasitol. 1990; 41:53–63.

26. Li J, Zhang X, Liu Q, Yin J, Yang J. Eimeria tenella: cloning of a novel Eimeria tenella cDNA encoding a protein related to rhomboid family from F2 hybrid strain. Exp Parasitol. 2006; 113:215–220.

27. Xu Q, Song X, Xu L, Yan R, Shah MA, Li X. Vaccination of chickens with a chimeric DNA vaccine encoding Eimeria tenella TA4 and chicken IL-2 induces protective immunity against coccidiosis. Vet Parasitol. 2008; 156:319–323.

28. Li J, Zheng J, Gong P, Zhang X. Efficacy of Eimeria tenella rhomboid-like protein as a subunit vaccine in protective immunity against homologous challenge. Parasitol Res. 2012; 110:1139–1145.

29. de Venevelles P, Chich JF, Faigle W, Loew D, Labbé M, Girard-Misguich F, Péry P. Towards a reference map of Eimeria tenella sporozoite proteins by two-dimensional electrophoresis and mass spectrometry. Int J Parasitol. 2004; 34:1321–1331.

30. Liu L, Xu L, Yan F, Yan R, Song X, Li X. Immunoproteomic analysis of the second-generation merozoite proteins of Eimeria tenella. Vet Parasitol. 2009; 164:173–82.

31. de Venevelles P, François Chich J, Faigle W, Lombard B, Loew D, Péry P, Labbé M. Study of proteins associated with the Eimeria tenella refractile body by a proteomic approach. Int J Parasitol. 2006; 36:1399–1407.

32. Schaap D, Arts G, Kroeze J, Niessen R, Roosmalen-Vos SV, de Venevelles P, François Chich J, Faigle W, Lombard B, Girard-Misguich F, Péry P. Towards a reference map of Eimeria tenella sporozoite proteins by two-dimensional electrophoresis and mass spectrometry. Int J Parasitol. 2004; 34:1321–1331.

33. Zhang X, Song X, Wang S, Lu M, Song X, Xu L, Yan R, Li X. The molecular characterization and immune protection of microneme 2 of Eimeria acervulina. Vet Parasitol. 2016; 215:96–105.

34. Huang J, Zhang Z, Li M, Song X, Yan R, Xu L, Li X. Immune protection of microneme 7 (EmMIC7) against Eimeria maxima challenge in chickens. Avian Pathol. 2015; 44: 392–400.
49. Wang S, Zhang Z, Wang Y, Gadahi JA, Xu L, Yan R, Song X, Li X. Toxoplasma gondii elongation factor 1-alpha is a novel vaccine candidate antigen against toxoplasmosis. Front Microbiol. 2017; 8:168.

50. Matsubayashi M, Teramoto-Kimata I, Uni S, Lillehoj HS, Matsuda H, Furuya M, Tani H, Sasai K. Elongation factor-1alpha is a novel protein associated with host cell invasion and a potential protective antigen of Cryptosporidium parvum. J Biol Chem. 2013; 288:34111–34120.

51. Han K, Xu L, Yan R, Song X, Li X. Vaccination of goats with glyceraldehyde-3-phosphate dehydrogenase DNA vaccine induced partial protection against Haemonchus contortus. Vet Immunol Immunopathol. 2012; 149:177–185.

52. Tallima H, Montash M, Veprek P, Velek J, Jezek J, El Ridi R. Differences in immunogenicity and vaccine potential of peptides from Schistosoma mansoni glyceraldehyde 3-phosphate dehydrogenase. Vaccine. 2003; 21:3290–3300.

53. Suresh S, Bressi JC, Kennedy KJ, Verlinde CL, Gelb MH, Hol WG. Conformational changes in Leishmania mexicana glyceraldehyde-3-phosphate dehydrogenase induced by designed inhibitors. J Mol Biol. 2001; 309:423–435.

54. Pereira JM, Severino RP, Vieira PC, Fernandes JB, da Silva MF, Zottis A, Andricopulo AD, Oliva G, Corrêa AG. Anacardic acid derivatives as inhibitors of glyceraldehyde-3-phosphate dehydrogenase from Trypanosoma cruzi. Bioorg Med Chem. 2008; 16:8889–8895.

55. Belluti F, Uliassi E, Veronesi G, Bergamini C, Kaiser M, Brun R, Viola A, Fato R, Michels PA, Krauth-Siegel RL, Cavalli A, Bolognesi ML. Toward the development of dual-targeted glyceraldehyde-3-phosphate dehydrogenase/trypaenothione reductase inhibitors against Trypanosoma brucei and Trypanosoma cruzi. ChemMedChem. 2014; 9:371–382.

56. Chen L, Yang D, Xie Y, Nong X, Huang X, Fu Y, Gu X, Wang S, Peng X, Yang G. Protection against Taenia pisiformis larval infection induced by a recombinant oncosphere antigen vaccine. Genet Mol Res. 2014; 13:6148–6159.

57. Bromley E, Leeds N, Clark J, McGregor E, Ward M, Dunn MJ, Tomley F. Defining the protein repertoire of microneme secretory organelles in the apicuclear parasite Eimeria tenella. Proteomics. 2003; 3:1553–1561.